NDA 021302 · Bausch
Elidel
Pimecrolimus · Topical · Calcineurin Inhibitor Immunosuppressant
NovelLast checked: Nov 19, 2026Latest source record: Jun 9, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Dec 13, 2001
Approved uses
1
Original approval plus efficacy supplements
Registered trials
65
15 Phase 3, 0 recruiting
FAERS reports
1,797
577 serious, 22 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED Although a causal relationship has not been established, rare cases of malignancy (e.g., skin and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including Pimecrolimus Cream, 1%. [see Warnings and Precautions (5.1) ] . Therefore: • Continuous long-term use of topical calcineurin inhibitors, including Pimecrolimus Cream, 1%, in any age group should be avoided and application limited to areas of involvement with atopic dermatitis [see Dosage and Administration (2) , Warnings and Precautions (5.1) ] . • Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4) ] . WARNING: LONG-TERM SAFETY OF TOPICAL CALCINEURIN INHIBITORS HAS NOT BEEN ESTABLISHED See full prescribing...
What it is approved for
From the label in effect Apr 30, 2026.
Pimecrolimus Cream, 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. Pimecrolimus Cream, 1% is not indicated for use in children less than 2 years of age [see Warnings and Precautions (5.1) , Use in Specific Populations (8.4) ] . Pimecrolimus Cream, 1% is a calcineurin inhibitor immunosuppressant indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. ( 1 )
Mechanism: The mechanism of action of pimecrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that pimecrolimus binds with high affinity to macrophilin-12 (FKBP-12) and inhibits the calcium-dependent phosphatase, calcineurin. As a consequence, it inhibits T-cell activation by blocking the transcription of early cytokines. In particular, pimecrolimus inhibits at nanomolar concentrations Interleukin-2 and interferon gamma (Th1-type) and Interleukin-4 and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 13, 2001 Original approval · Type 1 - New Molecular Entity NovelLabelReviewMedication Guide
1 products under this application
- ELIDEL · PIMECROLIMUS 1% · CREAM, TOPICAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Pimecrolimus" as an intervention, any sponsor and status, largest first.
- 5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
MEDA Pharma GmbH & Co. KGIndustry
NCT00120523 · 2,418 participants · Start Apr 2004 · Primary completion Oct 2010
Drug: Pimecrolimus; Topical corticosteroids · For: Atopic Dermatitis
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 31 sites in all
- Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease ModificationPivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT00124709 · 1,091 participants · Start Oct 2003 · Primary completion Jan 2008
Drug: Pimecrolimus; Corticosteroid · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Fayetteville, Arkansas; Jonesboro, Arkansas · 36 sites in all
- Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Glenmark Pharmaceuticals Ltd. IndiaIndustry
NCT02896101 · 755 participants · Start Aug 2016 · Primary completion Jun 2017
Drug: Pimecrolimus Cream, 1%; Elidel® (pimecrolimus) Cream and 1 more · For: Atopic Dermatitis
Sites: Hot Springs, Arkansas; Little Rock, Arkansas; Anaheim, California · 27 sites in all
- Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Mylan Inc.Industry
NCT03107611 · 654 participants · Start Feb 29, 2016 · Primary completion May 15, 2017
Drug: Pimecrolimus Cream, 1%; Placebo Cream and 1 more · For: Atopic Dermatitis
Sites: Boynton Beach, Florida; Coral Gables, Florida; Miami, Florida · 27 sites in all
- Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand DermatitisPivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00226707 · 652 participants · Start Jul 2004
Drug: Pimecrolimus Cream 1% · For: Chronic Hand Dermatitis
- Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Actavis Inc.Industry
NCT02791308 · 587 participants · Start Feb 2015 · Primary completion Jul 2016
Drug: Pimecrolimus Cream 1% (Valeant); Vehicle cream and 1 more · For: Atopic Dermatitis
Sites: Anniston, Alabama; Birmingham, Alabama; Mesa, Arizona · 53 sites in all
- Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic DermatitisPivotal-lookingCompleted
Par Pharmaceutical, Inc.Industry
NCT03297502 · 582 participants · Start Jun 2016 · Primary completion Jun 2017
Drug: pimecrolimus cream 1%; Elidel (pimecrolimus) cream 1% and 1 more · For: Atopic Dermatitis
- A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic OintmentPivotal-lookingTerminated
Famy Life Sciences, a Viatris CompanyIndustry
NCT06400511 · 477 participants · Start Apr 22, 2024 · Primary completion Sep 9, 2025
Drug: Pimecrolimus 0.3% Ophthalmic Ointment; Placebo Ophthalmic Ointment · For: Blepharitis
Sites: Pheonix, Arizona; Garden Grove, California; Glendale, California · 29 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective266
- dermatitis atopic212
- pruritus209
- rash193
- product use in unapproved indication131
- dry skin111
- eczema104
- off label use103
- injection site pain82
- skin exfoliation80
- erythema77
- sleep disorder due to a general medical condition73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 5 |
| 2008 | 8 |
| 2009 | 2 |
| 2010 | 7 |
| 2011 | 19 |
| 2012 | 5 |
| 2013 | 9 |
| 2014 | 13 |
| 2015 | 10 |
| 2016 | 15 |
| 2017 | 17 |
| 2018 | 40 |
| 2019 | 85 |
| 2020 | 102 |
| 2021 | 172 |
| 2022 | 200 |
| 2023 | 296 |
| 2024 | 274 |
| 2025 | 269 |
| 2026 | 242 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Elidel (Pimecrolimus)
2024 spending
$84K
Beneficiaries
77
118 claims
Per beneficiary
$1,092
$9.07 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,685,696 |
| 2021 | $1,124,301 |
| 2022 | $1,022,137 |
| 2023 | $869,997 |
| 2024 | $84,086 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials.
Chu DK, Chu AWL, Rayner DG, et al. · J Allergy Clin Immunol 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Treatment of oral lichen planus. Systematic review and therapeutic guide.
García-Pola MJ, González-Álvarez L, Garcia-Martin JM · Med Clin (Barc) 2017 · Systematic Review
- Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
- Oral lichen planus: comparative efficacy and treatment costs-a systematic review.
Sandhu S, Klein BA, Al-Hadlaq M, et al. · BMC Oral Health 2022 · Systematic Review
- Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Sigurgeirsson B, Boznanski A, Todd G, et al. · Pediatrics 2015 · Comparative Study, Multicenter Study
- Eczema.
Schmitt J, Apfelbacher CJ, Flohr C · BMJ Clin Evid 2011 · Systematic Review
Sponsor: Bausch
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.